209 related articles for article (PubMed ID: 9576286)
1. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
Rinne D; Baum RP; Hör G; Kaufmann R
Cancer; 1998 May; 82(9):1664-71. PubMed ID: 9576286
[TBL] [Abstract][Full Text] [Related]
2. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma.
Eigtved A; Andersson AP; Dahlstrøm K; Rabøl A; Jensen M; Holm S; Sørensen SS; Drzewiecki KT; Højgaard L; Friberg L
Eur J Nucl Med; 2000 Jan; 27(1):70-5. PubMed ID: 10654150
[TBL] [Abstract][Full Text] [Related]
3. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection.
Belhocine T; Pierard G; De Labrassinne M; Lahaye T; Rigo P
Oncologist; 2002; 7(4):271-8. PubMed ID: 12185291
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma.
Mijnhout GS; Comans EF; Raijmakers P; Hoekstra OS; Teule GJ; Boers M; De Gast GC; Adèr HJ
Nucl Med Commun; 2002 May; 23(5):475-81. PubMed ID: 11973489
[TBL] [Abstract][Full Text] [Related]
5. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
6. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact.
Stas M; Stroobants S; Dupont P; Gysen M; Hoe LV; Garmyn M; Mortelmans L; Wever ID
Melanoma Res; 2002 Oct; 12(5):479-90. PubMed ID: 12394190
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of positron emission tomography for the detection of melanoma metastases.
Holder WD; White RL; Zuger JH; Easton EJ; Greene FL
Ann Surg; 1998 May; 227(5):764-9; discussion 769-71. PubMed ID: 9605668
[TBL] [Abstract][Full Text] [Related]
9. Planar coincidence scintigraphy and PET in staging malignant melanoma.
Steinert HC; Voellmy DR; Trachsel C; Bicik I; Buck A; Huch RA; von Schulthess GK
J Nucl Med; 1998 Nov; 39(11):1892-7. PubMed ID: 9829578
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
11. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
[TBL] [Abstract][Full Text] [Related]
13. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma.
Kurli M; Reddy S; Tena LB; Pavlick AC; Finger PT
Am J Ophthalmol; 2005 Aug; 140(2):193-9. PubMed ID: 15992753
[TBL] [Abstract][Full Text] [Related]
14. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making.
Gulec SA; Faries MB; Lee CC; Kirgan D; Glass C; Morton DL; Essner R
Clin Nucl Med; 2003 Dec; 28(12):961-5. PubMed ID: 14663316
[TBL] [Abstract][Full Text] [Related]
15. Role of positron emission tomography in staging esophageal cancer.
Luketich JD; Schauer PR; Meltzer CC; Landreneau RJ; Urso GK; Townsend DW; Ferson PF; Keenan RJ; Belani CP
Ann Thorac Surg; 1997 Sep; 64(3):765-9. PubMed ID: 9307471
[TBL] [Abstract][Full Text] [Related]
16. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
[TBL] [Abstract][Full Text] [Related]
17. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.
Krug B; Dietlein M; Groth W; Stützer H; Psaras T; Gossmann A; Scheidhauer K; Schicha H; Lackner K
Acta Radiol; 2000 Sep; 41(5):446-52. PubMed ID: 11016764
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma.
Blessing C; Feine U; Geiger L; Carl M; Rassner G; Fierlbeck G
Arch Dermatol; 1995 Dec; 131(12):1394-8. PubMed ID: 7492127
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
